Literature DB >> 7996957

Gene therapy for arterial disease.

J M Isner1, L J Feldman.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7996957     DOI： 10.1016/s0140-6736(94)90454-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Hypoxically preconditioned human peripheral blood mononuclear cells improve blood flow in hindlimb ischemia xenograft model.

Authors:  Tomoaki Kudo; Masayuki Kubo; Shunsaku Katsura; Arata Nishimoto; Koji Ueno; Makoto Samura; Yasuhiko Fujii; Tohru Hosoyama; Kimikazu Hamano
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Vascular gene transfer.

Authors:  K M Channon; M A Blazing; S E George
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

3.  Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis.

Authors:  G Iaccarino; L A Smithwick; R J Lefkowitz; W J Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  [Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease].

Authors:  C Kalka; T Takahashi; H Masuda; T Asahara; J M Isner
Journal:  Med Klin (Munich)       Date:  1999-04-15

5.  Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit.

Authors:  L J Feldman; P G Steg; L P Zheng; D Chen; M Kearney; S E McGarr; J J Barry; J F Dedieu; M Perricaudet; J M Isner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation.

Authors:  Stefano Di Santo; Zijiang Yang; Moritz Wyler von Ballmoos; Jan Voelzmann; Nicolas Diehm; Iris Baumgartner; Christoph Kalka
Journal:  PLoS One       Date:  2009-05-21       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.